Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in children: A field guide
Malaria continues to be a major health problem in many parts of the world. Across the Sahel sub-region of Africa, most childhood malaria mortality and morbidity occurs during the rainy season, which is generally short. The provision of effective malaria treatment at intervals during this period has been shown to prevent illness and death from malaria among children.
Seasonal Malaria Chemoprevention (SMC) is a complete treatment course of amodiaquine plus sulfadoxine-pyrimethamine (AQ+SP) given at monthly intervals to children aged 3 to 59 months, beginning at the start of the transmission season (in areas where the therapeutic efficacy of AQ+SP remains high). It is recommended in areas of the Sahel sub-region with highly seasonal malaria transmission.
This guide provides the necessary technical and operational information and tools for country-level policy-makers and programme managers to decide on how to adopt and implement SMC.
- WHO policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa (March 2012)